Milestone Pharmaceuticals (MIST) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing innovative cardiovascular medicines, with a lead product candidate, etripamil, a rapid-onset nasal spray calcium channel blocker for self-administration targeting paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR).

• Aims to shift treatment of acute arrhythmias from emergency department settings to patient self-management, potentially reducing healthcare costs and improving patient outcomes.

• Incorporated in Canada, with U.S. operations, and qualifies as an emerging growth and smaller reporting company under U.S. securities laws.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, capital expenditures, and general corporate purposes.

• May allocate a portion to invest in or acquire complementary businesses or technologies, though no current plans for acquisitions.

• Pending use, proceeds will be invested in short-term, interest-bearing instruments.

Risk factors and disclosures

• Investment involves a high degree of risk, with risks detailed in the prospectus supplement and incorporated SEC filings.

• Risks include clinical, regulatory, financial, and competitive uncertainties, as well as potential for loss of investment.

• Forward-looking statements are subject to significant uncertainties and actual results may differ materially.